List of Differin drug patents
Differin is owned by Galderma Labs Lp.
Differin contains Adapalene.
Differin has a total of 9 drug patents out of which 4 drug patents have expired.
Expired drug patents of Differin are:
- US7834060
- US7868044
- US8703820
- US7838558
Differin was authorised for market use on 19 June, 2007.
Differin is available in gel;topical dosage forms.
Differin can be used as treatment of acne, topical treatment of acne vulgaris.
The generics of Differin are possible to be released after 31 May, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7834060 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders |
Mar, 2023
(15 days ago) | |
| US7868044 | GALDERMA LABS LP | Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid |
Mar, 2023
(15 days ago) | |
| US8703820 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(15 days ago) | |
| US7838558 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(15 days ago) | |
| US7737181 | GALDERMA LABS LP | Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Aug, 2024
(1 year, 5 months from now) | |
| US7579377 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Feb, 2025
(1 year, 10 months from now) | |
| US8709392 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
Sep, 2026
(3 years from now) | |
| US8435502 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers |
Sep, 2026
(3 years from now) | |
| US7998467 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
May, 2028
(5 years from now) | |
Drugs and Companies using ADAPALENE ingredient
Market Authorisation Date: 19 June, 2007
Treatment: Treatment of acne; Topical treatment of acne vulgaris
Dosage: GEL;TOPICAL
DIFFERIN family patents
22
United States
4
Japan
4
European Union
3
Australia
3
Russia
3
China
2
Denmark
2
France
2
Austria
2
Mexico
2
Slovenia
2
Germany
2
Argentina
2
Brazil
2
Portugal
2
Cyprus
2
Spain
2
Korea, Republic of
2
Canada
1
South Africa
1
IB
1
Hong Kong
1
Poland
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic